In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Brazil to supply WHO with Chagas disease treatment

This article was originally published in Scrip

Executive Summary

Lafepe, the publicly owned pharmaceutical laboratory of Pernambuco, Brazil, is to supply the WHOwith a Chagas disease treatment, benznidazole. The WHO recognition is a boost for the company, said Dr Davi Santana, Lafepe's technical director. "Becoming part of the group of suppliers to the WHO is not easy… They have very rigorous requirements, from the way we make medicines to the installations in our industrial complex," he said. The company, the only producer of benznidazole in the world, announced recently that it planned to make the first paediatric presentation available by the end of the year (Scrip Online, July 22nd, 2008). The company is also set to deliver on other big projects. "Developing efavirenz 600, a fixed dose antiretroviral and a fixed dose combination for TB are among our most important projects at the moment," Dr Leduar Guedes, Lafepe's technical superintendent told Scrip.

You may also be interested in...

NHS England And Vertex Strike “Lightening Quick” CF Kaftrio/Trikafta Deal

An agreement between Vertex and NHS England secures rapid access to Kaftrio, the company’s triple therapy for cystic fibrosis, including for patients with rare mutations not covered by the soon-to-be-granted European marketing authorization. The final price will depend on an assessment by health technology appraisal body NICE.

Will The COVID-19 Pandemic Shake Up Access To Medicines?

Public health advocates say that commercial concerns must take a back seat to health interests if COVID-19 technologies are to be made available to those who need them. But industry says that relaxing IP protections is not the solution and that many companies have already invested significant amounts of money in potential new treatments and vaccines.

Isatuximab EU Approval Decision Due

Recommending new medicines for approval and allowing sponsors of others extra time to answer outstanding questions are among the many tasks on the agenda of the March meeting of European Medicines Agency's key scientific committee, the CHMP. The meeting has been taking place, remotely, this week.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts